What is the PHO Performance Programme?
The purpose of the PHO Performance Programme is to improve equality and health outcomes for everyone accessing primary
healthcare in New Zealand. Performance based payments are made to PHOs to improve key indicators, which are reviewed annually.1 Not
all indicators attract funding, however, as some are provided for information only. Those indicators that are currently
funded are shown in Table 1. Performances are measured against ideal practice, adjusted to take into account factors such
as ethnicity and age that may differ between regions. In order to be eligible to enter the programme a PHO must meet and
then continue to fulfil the following prerequisites:1
- Minimum 85% ethnicity recording
- Minimum 70% valid NHI numbers on patient registers
- Compliance with the fees agreement
- Signed PHO agreement
- Complete practitioner information
- Complete PHO reporting
- Approved PHO performance plan
See “BPJ 36 (Jun, 2011) and BPJ
37 (Aug, 2011) for previous articles in this series.
Table 1: Funded PHO Performance Indicators for the period commencing 1 January, 2011
Cervical cancer screening
Breast cancer screening
Ischaemic cardiovascular disease detection
Cardiovascular disease risk assessment
Diabetes follow-up after detection
Influenza vaccine in people aged over 65 years
Age appropriate vaccinations for children aged two years
GP referred laboratory expenditure
GP referred pharmaceutical expenditure
PHO performance indicator for diabetes detection
Diabetes detection indicator definition
The PHO performance indicator and target for diabetes detection is: For 90% of enrolled patients with diabetes,
to have been identified and coded within their patient notes.
The purpose of the diabetes detection indicator is to determine what proportion of a PHO’s population estimated
to have diabetes has been diagnosed. The number of patients coded with diabetes is divided by the estimated prevalence
of diabetes (the denominator) within that PHO.
The estimated prevalence of diabetes within any PHO is derived from a national calculation of diabetes prevalence, which
is then adjusted to take into account individual PHO differences in age, gender and ethnicity. The national prevalence
data estimate is the number of people within New Zealand who have had diabetes related health service contact, divided
by the number of people in New Zealand, either enrolled with a PHO or having had contact with the New Zealand health service,
from 1 July 2009 to 30 June 2010.1
This may mean that in some cases, individual practices with excellent detection methods, may not appear to be meeting
the target if the actual prevalence of diabetes in their patient population is significantly less than that estimated
for their PHO. Conversely, some practices may have estimated detection rates of over 100%.
Diabetes detection comprises 9% of a PHO’s performance payment (3% for achieving the target in the total population
and 6% for achieving the target in the high
Conditions defined as diabetes
For the purpose of the PHO Performance Programme indicator, the term “diabetes” includes:
- Type 1 diabetes
- Type 2 diabetes
- Diabetes that could be either type 1 or type 2, but is clinically indeterminate
N.B. Gestational diabetes is excluded.
How should a diagnosis of diabetes be recorded?
To allow retrieval of information, electronic Read codes should be entered into the Patient Management System (PMS).
Consultations coded with a “diabetes mellitus” root Read code of C10. count towards achieving the PHO Performance
Programme target. The Read codes which are most commonly used, in practice, are outlined in Table 2.
N.B. Read codes C10A. (malnutrition-related diabetes) and C10B. (steroid-induced diabetes) are not eligible for counting
towards the target.
Table 2: Commonly used Read codes for diabetes for the PHO Performance Programme2
||Root Read Codew
|Type I Diabetes mellitus
|Type II Diabetes mellitus insulin dependent
|Type II Diabetes Mellitus non-insulin dependent
For a list of all Read codes that are identified for the PHO
Performance Programme see “Code Mappings for data transfer specification and clinical performance indicator data
format standard document.” Available from: www.dhbnz.org.nz/Site/SIG/pho/Technical-Documents.aspx
Who should be tested for diabetes?
Testing to detect pre-diabetes, or type 2 diabetes, should be considered in:
- People with symptoms of diabetes
- People at high risk of diabetes (see below)
- People having a cardiovascular risk assessment
Factors associated with an increased risk of diabetes include:
- Māori, Pacific, Asian or Indian ethnicity
- Age over 40 years
- Family history of type 2 diabetes (parent or sibling)
- Increased BMI and/or central obesity
- Impaired glucose tolerance or impaired fasting glycaemia
- Adverse lipid profile (especially low HDL and high triglycerides)
- High blood pressure
- History of gestational diabetes or have given birth to an infant weighing over 4 kg
- Polycystic ovary syndrome
- Taking medicines such as steroids or some antipsychotics
Fasting plasma glucose is the recommended initial test for detecting diabetes. Opportunistic (non-fasting) measurement
of HbA1c is appropriate if compliance with a fasting test is a barrier (Table 3).3
HbA1c is now the recommended test for diagnosis of Type 2 Diabetes. For more information, see "When to use fasting glucose to diagnose people with type II diabetes", BT 17 (December, 2012).
Table 3: Detecting diabetes3
|Fasting plasma glucose result
|≥ 7.0 mmol/L
||Repeat fasting plasma glucose, two results at this level constitute a diagnosis of diabetes
|6.1 – 6.9 mmol/L
||Request an oral glucose tolerance test (OGTT), indicates impaired fasting glucose
|5.5 – 6.0 mmol/L
||Request an OGTT if at high risk of diabetes
|≤ 5.4 mmol/L
||Retest in five years or earlier if risk factors, normal result
|≥ 6% (42 mmol/mol)
||Measure fasting plasma glucose
See “Detecting diabetes”,
bpacnz (Jul, 2008) for further information about testing.